BQ-3020BQ-3020
MedChemExpress (MCE)
HY-P1016
143113-45-5
Please store the product under the recommended conditions in the Certificate of Analysis.
Room temperature in continental US
may vary elsewhere.
BQ-3020 is a selective endothelin receptor (ETB receptor) agonist that displaces [125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research12.
BQ-3020 (0.01–300 nM, 7 min), produced concentration-dependent relaxationso on PhE-precontracted urothelium-denuded strips[1]. BQ-3020 (0.01–200 nM, 20 min) causes potent dose-dependent vasoconstriction with EC50 values of 0.57nM in rabbit pulmonary arteries by inhibiting ETB receptors[2]..
BQ-3020 (3 mg/kg for i.h., single dose) attenuates cancer pain by approximately 50% up to 3 h post-injection compared to PBS-vehicle and contralateral injection in cancer pain mouse model[3].
ETB 0.2 nM (IC50)
Ac-Leu-Met-Asp-Lys-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp
| | | |
| | | | | |
[1]. Arteaga JL,et.al. Endothelin ET(B) receptors are involved in the relaxation to the pig urinary bladder neck. Neurourol Urodyn. 2012 Jun
31(5):688-94. [Content Brief]
[2]. Ihara M, et.al. A novel radioligand [125I]BQ-3020 selective for endothelin (ETB) receptors. Life Sci. 1992
51(6):PL47-52. [Content Brief]
[3]. Quang PN, et.al. Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice. Pain. 2010 May
149(2):254-262. [Content Brief]